Successful autologous cell therapy
Autologous cell-based therapies are personalized therapies that use your own cells to target a disease or disorder. Cancer-targeted personalized therapies, such as CAR-T cell therapy, have produced impressive clinical results of complete remission rates for he B acute lymphoblastic leukemia in more than 80% of patients. One of the reasons this treatment is so successful is because it is autologous.
In 2017, the US FDA approved the first two CAR-T cell therapies. His Kymriah®, Novartis’ treatment for acute lymphoblastic leukemia (ALL), and his Yescarta, a Gilead subsidiary’s Kite, his pharma’s treatment for certain types of non-large B-cell lymphoma ®. – Hodgkin’s lymphoma. These autologous therapies are patient-specific when the therapeutic CAR-T cells are generated from the patient’s own cells.
The global CAR-T cell therapy market continues to grow due to new clinical and commercial developments in this therapy. As a result, the global CAR-T cell therapy market is expected to be worth $4.36 billion by 2028 from $2.31 billion in 2023, growing at a healthy CAGR of 13.5% during the forecast period.Companies like Pfizer PFE Johnson & Johnson JNJBMY Like Gilead Sciences guild All eyes are on this revolutionary CAR-T cell therapy.
The value of autologous stem cell therapy
Autologous stem cell therapy is a new medical technology that will revolutionize the way the medical community approaches the treatment of metabolic, autoimmune, and degenerative diseases. Additionally, the technology has been successfully used to develop skin grafts for wound care, treat burns and pressure ulcers, and speed recovery after surgery.
In this method, stem cells are extracted from the patient’s body and cultured in the laboratory before being reintroduced into the patient. Stem cells are a unique type of cell that can grow into other cells in the body. These ‘supercharged’ cells can be used to regenerate and repair tissue, making stem cells a powerful tool in modern personalized medicine. Stratified medicine cannot compete with this customization, precision, and safety profile.
A major advantage of using autologous cells is that they do not cause immunological rejection as they are derived from your own body. It also minimizes the risk of transmission from sources other than the patient. This allows autologous cell therapy to be used safely over the long term, and patients receive consistent and reliable treatment without the risk of rejection or complications due to mismatch.
The autologous cell therapy market was valued at $4.3 billion in 2021 and is projected to surge to $29.1 billion by 2031, with a compound annual growth rate (CAGR) of 21% from 2022 to 2031. Although the market is still in its infancy, it is expected to eventually create a new healthcare sector with similar revenues to the pharmaceutical, biotech, and medical device industries.
An autologous stem cell-based approach to treat disc pain
BioRestorative Therapies Inc. BRTXMore focuses on innovative ‘homemade’ autologous stem cell therapies to address the unmet needs of patients with common yet serious diseases. It was founded by doctors, scientists, and world-renowned stem cell researchers committed to developing new stem cell therapies.
The lead candidate for BioRestorative’s musculoskeletal stem cell platform is BRTX-100, which is administered as a single minimally invasive intradiscal injection. BRTX-100 is currently being evaluated in an FDA Gold Standard Phase 2, double-blind, randomized controlled trial in patients with chronic lumbar disc disease (cLDD).
Chronic lumbar disc disease affects more than 500 million people worldwide and is currently treatable only with opioids and surgery. Despite being the most commonly prescribed drug for cLLD, there are no clinical data supporting opioid use in cLLD, only adding to the opioid crisis in the United States.
Surgery for cLLD has many drawbacks and limitations. Surgery can be expensive. Surgical intervention may relieve pain in some cases, but often fails to restore previous levels of function and mobility. Revision or reoperation rates for spinal surgical interventions can exceed 20-30% of cases performed. Furthermore, longer recovery periods are associated with increased risk of spinal mechanical instability and potential failure rates compared to non-surgical treatments.
The BioRestorative Therapies and general autologous cell therapy markets appear to have a bright future as patients increasingly consider personalized alternatives to surgery and conventional medicine. The BRTX-100 is an innovative, minimally invasive technology set that revolutionizes back pain treatment.
More information about the company and its product candidates can be found at https://www.biorestorative.com.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended as investment advice.
Featured photo by nobeastsofierce on Shutterstock